Literature DB >> 28471725

How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?

Petr Szturz1, Tanguy Y Seiwert1, Jan B Vermorken1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28471725     DOI： 10.1200/JCO.2016.71.8072

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

1.  A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin.

Authors:  Luke S McLean; Tessa A Morris; Ann Gramza; Stephen Liu; Saad A Khan; A Dimitrios Colevas; Tillman Pearce; Danny Rischin
Journal:  Invest New Drugs       Date:  2022-04-18       Impact factor: 3.651

Review 2.  Metastatic disease in head & neck oncology.

Authors:  Paolo Pisani; Mario Airoldi; Anastasia Allais; Paolo Aluffi Valletti; Mariapina Battista; Marco Benazzo; Roberto Briatore; Salvatore Cacciola; Salvatore Cocuzza; Andrea Colombo; Bice Conti; Alberto Costanzo; Laura Della Vecchia; Nerina Denaro; Cesare Fantozzi; Danilo Galizia; Massimiliano Garzaro; Ida Genta; Gabriela Alejandra Iasi; Marco Krengli; Vincenzo Landolfo; Giovanni Vittorio Lanza; Mauro Magnano; Maurizio Mancuso; Roberto Maroldi; Laura Masini; Marco Carlo Merlano; Marco Piemonte; Silvia Pisani; Adriele Prina-Mello; Luca Prioglio; Maria Gabriella Rugiu; Felice Scasso; Agostino Serra; Guido Valente; Micol Zannetti; Angelo Zigliani
Journal:  Acta Otorhinolaryngol Ital       Date:  2020-04       Impact factor: 2.124

Review 3.  Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance.

Authors:  Nabil F Saba; Zhuo Gerogia Chen; Missak Haigentz; Paolo Bossi; Alessandra Rinaldo; Juan P Rodrigo; Antti A Mäkitie; Robert P Takes; Primoz Strojan; Jan B Vermorken; Alfio Ferlito
Journal:  Mol Cancer Ther       Date:  2019-11       Impact factor: 6.261

4.  Translating KEYNOTE-048 into practice recommendations for head and neck cancer.

Authors:  Petr Szturz; Jan B Vermorken
Journal:  Ann Transl Med       Date:  2020-08

5.  Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.

Authors:  Ines De Pauw; Filip Lardon; Jolien Van den Bossche; Hasan Baysal; Erik Fransen; Vanessa Deschoolmeester; Patrick Pauwels; Marc Peeters; Jan Baptist Vermorken; An Wouters
Journal:  Mol Oncol       Date:  2018-05-01       Impact factor: 6.603

6.  Choosing the Right Treatment Option for the Right R/M HNSCC Patient: Should We Adhere to PFE for First-Line Therapy?

Authors:  Katharina Lübbers; Mykola Pavlychenko; Theresa Wald; Susanne Wiegand; Andreas Dietz; Veit Zebralla; Gunnar Wichmann
Journal:  Front Oncol       Date:  2021-07-20       Impact factor: 6.244
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.